Vial

FEBRUARY 15, 2024

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030). Their ability to adapt to evolving regulations and industry standards reduces the likelihood of costly setbacks.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

Agency IQ

NOVEMBER 20, 2023

Summary of Product Characteristics and Package Leaflet), recommending that sponsors and regulators “explore the use of electronic media” to provide product information “in the future”. If the ePI is approved by the regulator, then it will be made publicly available in the ePI database.

Production 40

Production Packaging Hospitals Regulations 40

Drug Discovery World

JULY 11, 2022

The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1. As the field matures and the risks are better understood, regulators continue to streamline duplicative and burdensome oversight efforts 5. A quality system that is set up to handle both is required.

Therapies 130

Therapies Clinical Trials Production Trials 130

Agency IQ

MARCH 7, 2024

British regulators tease new device regulations in informative live session This week, the British regulator MHRA offered a new peek into its planned medical device regulations. BY COREY JASEPH, MS, RAC | MAR 5, 2024 11:10 PM CST Quick background on medical device regulation in the U.K. post-market regulation here.]

Regulations 40

Regulations International Government Production 40

Agency IQ

MARCH 15, 2024

California publishes draft regulations for landmark plastic pollution reduction act CalRecycle has launched the formal rulemaking process for Senate Bill 54, which will implement a sweeping plan to reduce plastic waste in the state by 2032. That amount will increase to 40% in 2030 and 65% in 2032.

Regulations 40

Regulations Packaging Compliance Production 40

Drug Discovery World

FEBRUARY 15, 2023

However, over the last few decades, it has been widely accepted that interaction between the tumour and host immune response plays a critical role in regulating tumour biology and hence its progression. Strategic Market Research Report; Immuno-oncology Assays Market Size, Trend Analysis 2030. & Allison, J. 90, 297–339 (2006).

Research 130

Research Therapies Immune Response Clinical Trials 130

Agency IQ

DECEMBER 15, 2023

The 174 regulations the EPA is currently working on The Environmental Protection Agency has unveiled its Fall 2023 Unified Agenda, which provides a look into the agency’s regulatory agenda for the upcoming year. The expected release dates of the agendas rarely line up exactly with the actual dates when the agency releases the regulation.

Regulations 40

Regulations Compliance Production Government 40

The Pharma Data

JANUARY 9, 2021

This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales. In working together, we envision protecting or enhancing 1 billion lives by 2030.

Government 52

Government Vaccine Production Licensing 52

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. In response to this hysteria, regulation was aggressively tightened. Between the technical uncertainty and the horrendous PR, pharmaceutical companies had little interest in adopting molecular farming technologies.

Engineering 87

Engineering Vaccine Production RNA 87

Agency IQ

JUNE 16, 2023

Highlights of the EPA’s Unified Agenda for Spring 2023 The Office of Management and Budget has released the Unified Agenda for Spring 2023, which outlines the regulations that agencies expect to release in 2023 and 2024. This information would be used in considering the regulation of asbestos.

Regulations 40

Regulations Compliance Production Science 40

The Pharma Data

DECEMBER 18, 2020

billion: Norway has signed a new commitment of NOK 1 billion to the International Finance Facility for Immunisation (IFFIm), to be paid from 2021 to 2030. It provides normative guidance on vaccine policy, regulation, safety, R&D, allocation, and country readiness and delivery. million in direct funding and $6.25

Vaccine 52

Vaccine Government International Virus 52